Relapsed Peripheral T-Cell Lymphoma: Clinical Trials

4 trials for Relapsed Peripheral T-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Recruiting 2

Follow Relapsed Peripheral T-Cell Lymphoma: new trials by email Literature Review of Relapsed Peripheral T-Cell Lymphoma trials Research Report on Relapsed Peripheral T-Cell Lymphoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Pembrolizumab IV infusion Q3W, with daily oral Olaparib. - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Phase 2RecruitingNational Cancer Centre, Singapore242024-07-012025-09-05
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Chidamide combined with Duvillisib - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Phase 2RecruitingThe First Affiliated Hospital of Xiamen University332023-11-222025-02-19
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Brentuximab Vedotin - induction, Gemcitabine, Brentuximab Vedotin - maintenance - Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Phase 2CompletedThe Lymphoma Academic Research Organisation712018-04-102025-07-30
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Folotyn and Leucovorin, Folic Acid, Vitamin B12 - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Phase 2CompletedAcrotech Biopharma Inc.362014-07-012019-11-20

Narrower conditions

Lymphoma, T-Cell, Peripheral (4)  ·  Lymphoma, T-Cell (2)

Broader conditions

Hemic and Lymphatic Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Lymphatic Diseases (4)  ·  Lymphoma (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Lymphoma, T-Cell (2)

Interventions

10-propargyl-10-deazaaminopterin (1)  ·  Brentuximab Vedotin (1)  ·  Folic Acid (1)  ·  Gemcitabine (1)  ·  Leucovorin (1)  ·  Vitamin B 12 (1)

Sponsors

Acrotech Biopharma Inc. (1)  ·  National Cancer Centre, Singapore (1)  ·  The First Affiliated Hospital of Xiamen University (1)  ·  The Lymphoma Academic Research Organisation (1)

Countries

Belgium (1)  ·  China (1)  ·  France (1)  ·  Singapore (1)  ·  United States (1)

Top investigators

Bing Xu (1)  ·  Jason YS Chan, MBBS, MRCP, MMed, FAMS, PhD (1)  ·  Wasim Khan, MD (1)

Results publications

PMID 40546726, PMID 40758949